Patents by Inventor Hiro Mizutani

Hiro Mizutani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the synthesis of E1 activating enzyme inhibitors
    Patent number: 10745404
    Abstract: The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 18, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20180079755
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((4S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 22, 2018
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Sulfamoylating reagents
    Patent number: 9802938
    Abstract: The present invention provides sulfamoylating reagents of formula RuN?—S(O)2X+, wherein X is a cyclic tertiary amine or a nitrogen-containing heteroaryl and Ru is an amine protecting group or hydrogen.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: October 31, 2017
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20150353555
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: November 25, 2014
    Publication date: December 10, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20150080573
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Publication number: 20080051404
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 28, 2008
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Claiborne, Stephen Critchley, Courtney Cullis, Steven Langston, Hiro Mizutani, Edward Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel Weatherhead